BR112014000275A2 - formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat) - Google Patents

formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat)

Info

Publication number
BR112014000275A2
BR112014000275A2 BR112014000275A BR112014000275A BR112014000275A2 BR 112014000275 A2 BR112014000275 A2 BR 112014000275A2 BR 112014000275 A BR112014000275 A BR 112014000275A BR 112014000275 A BR112014000275 A BR 112014000275A BR 112014000275 A2 BR112014000275 A2 BR 112014000275A2
Authority
BR
Brazil
Prior art keywords
mechanical ventilation
pavm
vat
aminoglycoside
combinations
Prior art date
Application number
BR112014000275A
Other languages
English (en)
Inventor
Bruce Montgomery Alan
Original Assignee
Cardeas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardeas Pharma Inc filed Critical Cardeas Pharma Inc
Publication of BR112014000275A2 publication Critical patent/BR112014000275A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A61M16/16—Devices to humidify the respiration air

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat). a presente invenção é composições de antibióticos, sistemas à base de ventilação e métodos relacionados a pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat). as combinações de antibióticos e um aminoglicosídeo, de preferência, amicacina, são administradas via um nebulizador acoplado dentro da passagem de ar do ventilador. condições umidificadas criam uma névoa aperfeiçoada de aerossol para tratar pavm e vat.
BR112014000275A 2011-07-12 2012-07-12 formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat) BR112014000275A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161572225P 2011-07-12 2011-07-12
PCT/US2012/046559 WO2013010041A1 (en) 2011-07-12 2012-07-12 Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis

Publications (1)

Publication Number Publication Date
BR112014000275A2 true BR112014000275A2 (pt) 2017-04-18

Family

ID=46545929

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014000275A BR112014000275A2 (pt) 2011-07-12 2012-07-12 formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat)

Country Status (12)

Country Link
US (2) US10471083B2 (pt)
EP (1) EP2731586B1 (pt)
JP (2) JP2014523909A (pt)
KR (1) KR20140025534A (pt)
CN (1) CN103702663A (pt)
AU (2) AU2012281068A1 (pt)
BR (1) BR112014000275A2 (pt)
CA (1) CA2841272C (pt)
MX (1) MX2014000540A (pt)
RU (1) RU2014101763A (pt)
WO (1) WO2013010041A1 (pt)
ZA (2) ZA201309028B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2622193A1 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
US9861616B2 (en) * 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
TWI571259B (zh) * 2013-03-15 2017-02-21 卡帝俄斯製藥公司 胺基糖苷及磷黴素組合之改良調配物及用於治療呼吸器相關性肺炎（ｖａｐ）與呼吸器相關性氣管（ｖａｔ）支氣管炎之方法及系統
EP3038599A1 (en) 2013-08-26 2016-07-06 Cardeas Pharma Inc. Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties
WO2019002033A1 (en) 2017-06-28 2019-01-03 Koninklijke Philips N.V. SYSTEM FOR HUMIDIFYING A PRESSURIZED FLOW OF BREATHING GAS DELIVERED TO A PATIENT

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
HUP0105226A3 (en) 1998-12-17 2003-03-28 Pathogenesis Corp Seattle Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic
MXPA02010884A (es) 2000-05-05 2003-03-27 Aerogen Ireland Ltd Aparato y metodo para el suministro de medicamentos al sistema respiratorio.
US7971588B2 (en) * 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
US7100600B2 (en) 2001-03-20 2006-09-05 Aerogen, Inc. Fluid filled ampoules and methods for their use in aerosolizers
CA2447600C (en) 2001-05-18 2015-10-20 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
ES2603067T3 (es) 2002-01-15 2017-02-23 Novartis Ag Métodos y sistemas para hacer funcionar un generador de aerosol
US7607436B2 (en) 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
ITMI20021881A1 (it) 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
ES2327935T3 (es) 2003-11-17 2009-11-05 Nektar Therapeutics Introduccion de un aerosol en un circuito de un ventilador.
ES2392389T3 (es) 2004-05-17 2012-12-10 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
PT1765288E (pt) 2004-06-18 2013-01-29 Novartis Ag Métodos de tratamento de infeções endobrônquicas
US20090032427A1 (en) 2005-09-29 2009-02-05 Nektar Therapeutics Receptacles and Kits, Such as for Dry Powder Packaging
CA2622193A1 (en) 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
CA2672261C (en) 2006-12-11 2014-09-23 Drugrecure Aps Methods for treating cystic fibrosis or pneumonia with bacterial infection via pulmonary administration of fosfomycin
BRPI0817311A2 (pt) 2007-09-25 2015-03-17 Novartis Ag Tratamento de doenças pulmonares com medicamentos em aerossol tais como a vancomicina
GB0813211D0 (en) 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
JP2012522009A (ja) 2009-03-26 2012-09-20 パルマトリックス，インコーポレイテッド 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
CA2780138A1 (en) 2009-11-24 2011-06-03 Gilead Sciences, Inc. Inhaled fosfomycin/tobramycin for the treatment of chronic obstructive pulmonary disease
EP2567691B1 (en) 2011-09-12 2014-12-24 Meiji Seika Pharma Co., Ltd. Aqueous compositions comprising arbekacin

Also Published As

Publication number Publication date
AU2016202244A1 (en) 2016-05-05
US20140221302A1 (en) 2014-08-07
CA2841272C (en) 2019-01-15
CN103702663A (zh) 2014-04-02
US8603439B2 (en) 2013-12-10
JP2015232026A (ja) 2015-12-24
CA2841272A1 (en) 2013-01-17
ZA201409204B (en) 2016-10-26
ZA201309028B (en) 2015-08-26
RU2014101763A (ru) 2015-08-20
US20130014759A1 (en) 2013-01-17
EP2731586A1 (en) 2014-05-21
AU2012281068A1 (en) 2013-12-19
WO2013010041A1 (en) 2013-01-17
US10471083B2 (en) 2019-11-12
JP2014523909A (ja) 2014-09-18
KR20140025534A (ko) 2014-03-04
MX2014000540A (es) 2014-05-01
EP2731586B1 (en) 2019-09-25

Similar Documents

Publication Publication Date Title
BR112014000275A2 (pt) formulações aperfeiçoadas de combinações de aminoglicosídeo e fosfomicina e métodos e sistemas para o tratamento de pneumonia associada à ventilação mecânica (pavm) e traqueobronquite associada à ventilação mecânica (vat)
MX336260B (es) Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
MX2008010222A (es) Antibioticos nebulizados para terapia de inhalacion.
UY32174A (es) Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
IN2014MN00862A (pt)
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX363007B (es) Uso de n-acetil-5-metoxi-triptamina o analogos de la misma para potenciar el mecanismo de implantacion del embrion, y composiciones y medios de cultivo relacionados.
BR112015026513A2 (pt) derivados de n-piperidin-3-ilbenzamida para tratar as doenças cardiovasculares
CY1118858T1 (el) Νεα παραγωγα πυριμιδινης, παρασκευη αυτων και φαρμακευτικη χρηση αυτων ως αναστολεων φωσφορυλιωσης ακτ(ρκβ)
CL2016001543A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas.
MX352760B (es) Metodos para tratar infecciones intrapulmonares.
UY32167A (es) Nuevos derivados de 2-amidotiadiazol
BRPI0913297B8 (pt) composição farmacêutica estabilizada
BR112012019920A2 (pt) derivados de piridazina úteis como agonístas de canabinoide-2.
PH12016500384A1 (en) Formulations of aminoglycosides and fosfomycin in a combination having improved chemical properties
BR112012033121A2 (pt) métodos e composições farmacêuticas para o tratamento de infecções do trato respiratório.
MX347541B (es) Analogos de acido sialico.
WO2012177075A3 (ko) 항생제 및 라이소포스파티딜콜린을 포함하는 면역 증강 또는 세균성 감염 질환 치료용 조성물
BR112014028632A8 (pt) Composto, composição farmacêutica, e, método para preparar um composto
IN2014DN03010A (pt)
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos
BR112017019918A2 (pt) preparação sólida farmacêutica, e, método para produzir uma preparação sólida farmacêutica para estabilizar uma preparação sólida farmacêutica
BR112016029926A2 (pt) administração nasal
MX2011002874A (es) Novedosas formulaciones de carbapenem aminoglicosido como una sola unidad.
NI201200045A (es) Composiciones y métodos para tratar infecciones bacterianas utilizando ceftarolina

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: CARDEAS PHARMA INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25E Requested change of name of applicant rejected

Owner name: CARDEAS PHARMA INC. (US)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2470 DE 08-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.